Profile | GDS2987 / GI_33354280-A |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 15.8 | 48 |
GSM215244 | HMVEC_vehicle_rep2 | 10.1 | 26 |
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | 5.8 | 16 |
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | 4.6 | 17 |
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | 2.4 | 4 |
GSM215297 | PASMC_vehicle_rep1 | 24.8 | 36 |
GSM215298 | PASMC_vehicle_rep2 | 42.2 | 54 |
GSM215310 | PASMC_vehicle_rep3 | 47.6 | 59 |
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | 17.6 | 28 |
GSM215313 | PASMC_atorvastatin_rep3 | ||
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 35.5 | 51 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 18.2 | 34 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 26.9 | 42 |
GSM215327 | PASMC_SLx2119_rep1 | 7.9 | 14 |
GSM215328 | PASMC_SLx2119_rep2 | 16.4 | 30 |
GSM215329 | PASMC_SLx2119_rep3 | 16 | 30 |
GSM215330 | Fibroblasts_vehicle_rep1 | 140.5 | 78 |
GSM215331 | Fibroblasts_vehicle_rep2 | 111.7 | 76 |
GSM215332 | Fibroblasts_vehicle_rep3 | 103.8 | 76 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 115.6 | 77 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 163.5 | 79 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 142.9 | 78 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 135.4 | 78 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 135.4 | 78 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 140.3 | 78 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 155.1 | 79 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 124.3 | 77 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 145.1 | 78 |